ZPBP

Across TCGA pan-cancer cohorts, ZPBP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZPBP data layer compared with 18 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZPBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZPBP expression acts as an unfavorable survival marker.

LIHC, COAD, and MESO are the cancer types where ZPBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.020	0.779	<.001	18	view →
COAD	OS	Median	III,IV	0.163	0.791	.004	15	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
LGG	OS	Median	All	0.238	0.810	.001	12	view →
SARC	OS	Median	All	0.241	0.766	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZPBP–LIHC (OS)

Open the LIHC breakdown →